Ardelyx, INC Form 4 insider transactions

Elizabeth A. Grammer, Chief Legal and Administrative Officer of Ardelvx, Inc., reports exercising stock options and selling shares of common stock on May 6, 2024.

Elizabeth Grammer, Chief Legal and Administrative Officer of Ardelvx, Inc., sold 45,000 shares of common stock at $9 per share on May 3, 2024, under a pre-arranged 10b5-1 trading plan.

Laura A. Williams, Chief Medical Officer of Ardelvx Inc., exercised stock options and sold shares on May 3, 2024, according to a Form 4 filing with the SEC.

Ardelvx's CEO, Michael Raab, exercised stock options and sold 30,000 shares of common stock at an average price of $6.4019, according to a Form 4 filing.

Ardelix's CEO, Michael Raab, sold 7,500 shares of common stock at an average price of $7.0565 on April 15, 2024, under a pre-arranged 10b5-1 trading plan.

Michael Raab, President and CEO of Ardelyx, Inc., reports the sale of 1,518 shares of common stock at $7.31 per share under a pre-arranged 10b5-1 trading plan.

Mike Kelliher, Executive Vice President at Ardelix, reports acquiring 160,000 shares of common stock and stock options for 205,000 shares on March 25, 2024.

Robert Blanks, Chief Regulatory and Quality Affairs Officer at Ardelvx, reports gifting 1,000 common shares on March 15, 2024.

Elizabeth Grammer, Chief Legal and Administrative Officer of Ardelrx, Inc., sold 86,000 shares of common stock at an average price of $7.7323 per share on March 20, 2024, under a pre-arranged 10b5-1 trading plan.

David P. Rosenbaum, Chief Development Officer of Ardelvx, Inc., reported the sale of 5,183 shares of common stock at $9.2 per share on February 26, 2024.